{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-007474","form_type":"8-K","ticker":"BAX","cik":"0000010456","company_name":"BAXTER INTERNATIONAL INC","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.454491+00:00","generated_at":"2026-05-16T02:54:23.803356+00:00","sec_items":["2.02","8.01","5.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Baxter Q4 GAAP EPS loss ($2.01), adj. $0.44; sales $2.97B +8%; div cut to $0.01","bullets":["Q4 sales $2.97B (+8% reported, +3% operational); GAAP diluted EPS loss ($2.01), adjusted diluted EPS $0.44.","Board appoints Michael R. McDonnell (former Biogen CFO); directors Cathy Smith and Stephen Rusckowski resign effective Feb 13.","Quarterly dividend declared at $0.01 per share, payable April 1, 2026 to holders of record Feb 27, 2026.","CEO Hider: Q4 results missed expectations; new operating model aims to simplify organization and accelerate innovation."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-007474","json":"https://secwatch.observer/filing/0001628280-26-007474.json","markdown":"https://secwatch.observer/filing/0001628280-26-007474.md","text":"https://secwatch.observer/filing/0001628280-26-007474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/10456/000162828026007474/0001628280-26-007474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10456/000162828026007474/bax-20260210.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:54:23.803356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}